Olfactory receptors (ORs) recognize odorant molecules and BACKGROUND: activate a signal transduction pathway that ultimately leads to the perception of smell. This process also modulates the apoptotic cycle of olfactory sensory neurons in an olfactory receptor-specific manner. Recent reports indicate that some olfactory receptors are expressed in tissues other than the olfactory epithelium suggesting that they may have pleiotropic roles.
Introduction
The olfactory receptors (ORs) represent the largest multi-gene family in the human genome and account for approximately 400 functional genes and 4-500 pseudogenes 1, 2 . ORs encode G-protein-coupled receptor proteins that bind volatile molecules via their extracellular domain. Upon binding, they activate a signal transduction pathway that results in the generation of an electrical signal in olfactory sensory neurons (OSNs) which, after integration in the brain, results in the perception of smell 1, 3 . This process involves the activation of a heterotrimeric G protein by the OR, that in turn activates adenylate cyclase resulting in the production of cyclic AMP (cAMP). cAMP acts as a second messenger that opens cyclic nucleotide gated channels which allow the depolarization of the membrane and the generation of an action potential in the activated OSN 4 . In parallel, ligand binding also activates pathways involved in survival and proliferation 5 , such as the MAPK, Rho and AKT signalling cascades 6, 7 . Additionally, some ORs share high levels of identity with chemokine receptors and as such play a role in migration; indeed ORs mediate the projection of the OSN axons towards odorant-specific glomerular structures in the olfactory bulb 8 .
ORs are frequently neglected in cancer genomic and transcriptomic studies because it is assumed that their specialised role in the olfactory epithelium makes them unlikely to contribute to cancer development. Nonetheless, their ability to sense small organic molecules, combined with the transduction of a survival signal and/or a migratory stimulus could render them functional in cancer cells [9] [10] [11] . In OSNs the ORs bind their ligand(s) in solution within the liquid layer of mucus 12 , consequently they may be functionally triggered in other body fluids. Moreover . Recent studies have also shown that OR51E2 (also known as PSGR) is involved in the regulation of prostate cancer cell migration and proliferation, and is a potential marker of patient outcome [20] [21] [22] . Therefore, we sought to evaluate the profile of OR expression in cancer cell lines and cancers.
Methods

Datasets and analysis
We investigated the expression of olfactory receptors in a broad panel of 968 cancer cell lines, using the RMA-normalised 23 microarray expression data available for each of 17,419 loci (annotation BrainArray v.10 24 ). Data were available for each cell line in the deeply characterized COSMIC cell line collection (Iorio et al. 25 ). Information on these cancer cell lines is available from the COSMIC website: http://cancer.sanger.ac.uk/cell_lines. Raw expression data is publicly available via ArrayExpress (accession number: E-MTAB-3610; https://www.ebi.ac.uk/arrayexpress/experiments/E-MTAB-3610/).
To determine the level of expression of OR genes compared to the whole transcriptome, we applied mixture-distribution approaches described previously 26, 27 . Briefly, we imported the cancer COSMIC cell line microarray data into R 3.2. We then binned the expression level of all the detected genes. By evaluating the frequency of genes included in each bin for an arbitrary cell line, we confirmed that the distribution of expression levels across the transcriptome was bimodal. Then for each cell line, we used the mixtools package (v1.0.4, available from CRAN) described in detail in 27 to perform an E-M (expectation-maximisation) algorithm decomposition of the observed bimodal distribution into two normal distributions. This approximated the classification of all genes into highly expressed and poorly/lowly expressed genes: note that the algorithm iteratively estimates both the mean and variance of each component distribution and the probability of any one observation of gene expression belonging to the "high" or "low" distributions. As an exemplar in Figure 1 , we displayed the distribution of all gene-expression for cell line 905956, and plotted the algorithm-derived probabilities of any one gene belonging to low/high distributions using the mixtools "plot.EM" method. To create Supplementary Table 2, we noted the reported probabilities of any OR (and their effectors) belonging to the high or low distribution across all samples, where a gene was "highly expressed" if it had a 95% probability of belonging to the highly expressed geneset/ distribution. For the OR2C3 gene we performed a complementary analysis, where we varied the threshold probability needed to belong to the "highly expressed" geneset from 12.5% to 95%, and found the number of melanoma/non-melanoma cell lines with OR2C3 as "highly expressed" (Figure 2 ).
The log-transformed RSEM (RNA-Seq by Expectation-Maximization)-normalised Illumina transcriptome sequencing data for human melanoma tumours 28 , available via the TCGA website, were analysed for bimodality in the same way (Figure 3) . The results shown here are in whole or part based upon data generated by the TCGA Research Network: http://cancergenome.nih.gov/.
We interrogated the expression of OR2C3 in normal tissues from 2 repositories: BioGPS and GTEx. BioGPS contains expression levels from U133plus2 Affymetrix microarrays for 130 tissue types; the values shown on the Y axis are z-scores produced by the barcode function of the R package "frma" v1.0.0 (http://www. bioconductor.org/packages/2.6/bioc/html/frma.html) ( Figure 4A ). A z-score >5 suggests that the gene is expressed. As reference for the background signal, the first column represents yeast RNA hybridization (value outlined with the green dashed line). These data are available at: http://ds.biogps.org/?dataset=BDS_ 00001&gene=81472. GTEx Analysis Release v6 (dbGaP accession number: phs000424.v6.p1) shows expression values as log(RPKM) (Reads Per Kilobase of transcript per Million mapped reads) from 53 tissue types, calculated from a gene model with isoforms collapsed to a single gene ( Figure 4B ). Box plots are shown as median and 25th and 75th percentiles; points are displayed as outliers if they are above or below 1.5 times the interquartile range.
We used data from the ENCODE database (www.encodeproject. org; accession number: SRP039354) for the samples NHEM.f_M2_ Rep1, NHEM.f_M2_Rep2, NHEM_M2_Rep1, NHEM_M2_Rep2. For the interrogation of OR2C3 expression we used the expression values provided as fragment per kilobase per million mapped reads (FPKM). We interrogated The Human Protein Atlas database 29 (http://www. proteinatlas.org/) to investigate the expression of OR2C3 protein in melanoma tumor samples. By gene symbol we interrogated the protein expression of OR2C3 in different types of cancer.
Results and discussion
Since the OR family represents around 3% of human genes and encodes proteins with the ability to transduce survival signals, we hypothesized that aberrant expression of ORs in cancer cells may contribute to cancer cell survival, proliferation and migration. To support the validity of this hypothesis, we investigated the expression of OR genes in a comprehensive panel of 968 cell lines from COSMIC 30 . Overall we could interrogate the expression of 301 OR genes in this microarray gene expression dataset (Supplementary Table 1 ). The distribution of expression levels across the transcriptome was found to be bimodal; when decomposed into two normallike distributions, OR genes could be separated into those that were lowly expressed, and others that were highly expressed 26, 27 ( Figure 1A , green and red lines, respectively). OR genes were generally found to be expressed at low levels in cancer cell lines when compared to the distribution of expression levels of the whole transcriptome (see green bars in Figure 1A) , with most of the cell lines displaying very low levels of expression of most OR genes (examples in Figure 1B-C) . However, several cell lines displayed much higher expression of one or a few receptor genes that differentiate them from the other ORs, ranking these ORs amongst the set of genes defined as highly expressed when compared to the whole transcriptome (for instance OR2C3 in Figure 1A , 1D-E). In order to define OR genes expressed at high levels in each cell line, we identified those ORs having a 95% or greater probability of belonging to the distribution of highlyexpressed genes (Supplementary Table 2 and Supplementary Table 3 , see details of the approach in Methods). Overall, with this criterion, 56 (18.6%) OR genes are expressed in at least one cancer cell line, and 476 (49.2%) cell lines express at least one OR gene. Interestingly, 332 (69.7% of those expressing at least one OR) cell lines express only one specific receptor; this pattern of a single highly expressed OR was previously shown to be indicative of the functional receptor in an OSN 31 . Some OR genes displayed high expression in several cell lines from different tumour types, such as OR4A47, OR1D5, OR4C46 and OR6B2. Others ORs were primarily expressed in a single tumour type, such as OR13A1 and OR2C3 in B cell malignancies and melanoma, respectively (Supplementary Table 2 and Supplementary Table 3) . Additionally, we found that 85.95% of cell lines expressing an OR also express the functional effectors necessary for signal transduction (i.e. one of the alpha subunits of a G protein: GNA15, GNA13, GNAO1, GNAI1, GNAL and adenylate cyclase III ADCY3, see Supplementary Table 4 ). Therefore, most of the cell lines expressing an OR have the molecular machinery required to transduce signals from the OR to downstream pathways.
At the 95% threshold defined above, OR2C3 is expressed in 8 out of 52 melanoma cell lines (15.4%, Supplementary Table 4 ). Remarkably, the specificity of OR2C3 expression in melanoma cell lines is highly consistent since decreasing the probability threshold of OR expression still showed melanoma specific expression of OR2C3 (Figure 2) , further supporting the validity of our analysis. OR2C3 maps within an OR cluster located towards the telomeric end of chromosome 1 (1q44), and is not in the immediate vicinity of any established melanoma oncogenes whose deregulation/amplification could interfere with its expression.
To further explore the expression of OR2C3 we interrogated a collection of human melanomas whose expression profile has been defined by RNA sequencing (TCGA 28 , N=474 melanomas). We applied the same approach described above and found that 14 (3%) melanomas expressed OR2C3 (Supplementary Table 5 ) and found that OR2C3 is not expressed in any normal tissues (N=130 tissue types by BioGPS, N=53 tissue types by GTEx, Figure 4) . Further, we found that OR2C3 is not expressed in epidermal melanocyte samples from ENCODE (n=4, Supplementary Table 7) , thus suggesting cancer-specific expression. We next interrogated The Human Protein Atlas database 29 for OR2C3 expression and found that 1 out of 11 melanoma samples express medium levels of OR2C3 protein. Together these results indicate the OR2C3 is specifically expressed in a fraction of melanomas and supports a possible role for this gene in melanoma development.
Conclusion
We conclude that, far from being just highly specialized components of the olfactory sub-genome, olfactory receptors should be considered as candidate cancer genes and warrant detailed functional investigation. In particular, we provided different lines of evidence that support a potential functional role for OR2C3 in melanoma.
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